1.Expression of TLR4 and CXCR7 in gastric carcinoma and its relationship with HP positive infection
Zhaogen CAI ; Zenong CHENG ; Dapeng LI
Chinese Journal of Primary Medicine and Pharmacy 2017;24(16):2422-2426,后插3
Objective To explore the role and mechanism of Toll-like receptor 4(TLR4)and chemokine receptor 7(CXCR7)in the pathogenesis and development of Helicobacter pylori(HP)positive gastric cancer.Methods Tissues of 147 cases with gastric carcinoma and 60 normal control were collected.The protein expression of TLR4,CXCR7 was detected by immunohistochemical staining.HP infection in these samples were detected by immunohistochemistry and Gram staining.Results The positive rates of TLR4 and CXCR7 in gastric cancer tissues were 63.9% and 62.6%,respectively,which were significantly higher than those in normal control group(15.0% and 5.0%,respectively;X2=40.832,56.901,all P<0.01).The positive rates of TLR4 and CXCR7 in patients with lymph node metastasis were significantly higher than those without lymph node metastasis(X2=9.809,11.444,all P<0.01).The positive rates of TLR4 and CXCR7 in patients with stage Ⅲ and Ⅳ were significantly higher than those of stageⅠand Ⅱ(X2=24.927,27.642,all P<0.01).The expression of TLR4 and CXCR7 in gastric carcinoma was significantly related to HP infection.Kaplan-Meier survival analysis showed that the survival rates in TLR4 and CXCR7 positive group were significantly lower than those in TLR4 and CXCR7 negative groups(F=4.053,4.091,all P<0.05).COX regression analysis indicated that the TNM stage,the expression of TLR4 and CXCR7 were independent prognosis factors of gastric carcinoma.Conclusion TLR4 and CXCR7 are closely related to the occurrence and development of gastric cancer,and may play an important role in HP carcinogenesis.It may be involved in the invasion and metastasis of gastric cancer cells via LPS/TLR4 signaling pathway.
2.Research on FDA Data Standards Program in the United States and Its Enlightenment to China
Zhaogen CHENG ; Huang HUANG ; Mengyao LIN
China Pharmacy 2020;31(20):2438-2444
OBJECTIVE:To study FDA data standards program in the United States ,and to provide reference for constructing medicine data standards in China. METHODS :By analyzing the governance organization and policy system of FDA data standards program in the United States ,the experience were summarized for data standards development mode and development procedure , and relevant suggestions were put forward for medicine data standards construction in China. RESULTS & CONCLUSIONS :The organization of FDA data standards program is led by the Chief Scientist Office of FDA ,coordinated by the Data Standards Advisory Board ,specifically responsible by the Data Standards Program Board under the center for Drug Evaluation and Research , and participated by other regulatory centers and offices under FDA. FDA data standards program is composed of 4 subsystems as data standards strategy ,data standards program action plan ,data standards catalog and data standard communication plan. According to the federal laws and regulations of the United States ,the demand of FDA and pharmaceutical industry for data standards and the importance of data standards ,the strategic objectives of data standards development are proposed ,and the strategic objectives are refined into specific projects through the data standards program action plan. These programs strictly follow the“data standards development process ”and gradually advance quarterly ,and new data standards will be included in the Data Standards Catalog . At the same time ,FDA strengthen the cooperation and communication with internal and external stakeholders through the data standards program communication plan. It is suggested that China should learn from the experience of FDA data standards program construction ,establish a medical and health data standards program management mode ,strengthen the participation of internal and external stakeholders ,establish data standards committee ,formulate data standards catalog ,and provide clear and unified data standards for the pharmaceutical industry ,so as to promote the construction of medicine data standards in China.